ClariVest Asset Management LLC grew its position in Chemed Corp. (NYSE:CHE) by 9.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 21,655 shares of the company’s stock after acquiring an additional 1,827 shares during the period. ClariVest Asset Management LLC owned 0.14% of Chemed Corp. worth $4,375,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Acrospire Investment Management LLC bought a new position in shares of Chemed Corp. in the 2nd quarter valued at $120,000. Pacad Investment Ltd. lifted its stake in shares of Chemed Corp. by 250.0% in the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after acquiring an additional 500 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Chemed Corp. by 1,504.5% in the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after acquiring an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Chemed Corp. by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after acquiring an additional 83 shares during the last quarter. Finally, MCF Advisors LLC bought a new position in shares of Chemed Corp. in the 3rd quarter valued at $152,000. Institutional investors own 96.50% of the company’s stock.
In related news, Director Patrick P. Grace sold 500 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total transaction of $100,740.00. Following the completion of the transaction, the director now directly owns 4,515 shares of the company’s stock, valued at approximately $909,682.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the transaction, the insider now directly owns 37,809 shares of the company’s stock, valued at $7,465,765.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,229 shares of company stock valued at $7,556,478. 4.90% of the stock is owned by corporate insiders.
CHE has been the subject of a number of research reports. TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. increased their price target on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target for the company in a research note on Friday, July 28th. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 price target on shares of Chemed Corp. in a research note on Monday, July 31st. Finally, BidaskClub cut Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $236.00.
Shares of Chemed Corp. (CHE) traded down $1.46 during trading hours on Monday, reaching $231.61. The company had a trading volume of 96,000 shares, compared to its average volume of 94,289. The company has a market cap of $3,697.89, a price-to-earnings ratio of 28.52, a P/E/G ratio of 4.90 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. Chemed Corp. has a twelve month low of $145.35 and a twelve month high of $235.96.
Chemed Corp. (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. Chemed Corp.’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.73 EPS. equities analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 13th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 0.48%. The ex-dividend date of this dividend is Friday, November 10th. Chemed Corp.’s dividend payout ratio is currently 24.89%.
Chemed Corp. Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.